NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free KRRO Stock Alerts $46.40 +1.66 (+3.71%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$42.53▼$47.0050-Day Range$44.74▼$89.7452-Week Range$9.15▼$97.91Volume53,794 shsAverage Volume42,396 shsMarket Capitalization$430.13 millionP/E RatioN/ADividend YieldN/APrice Target$122.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Korro Bio alerts: Email Address Korro Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside164.0% Upside$122.50 Price TargetShort InterestHealthy2.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$999,992 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($9.64) to ($10.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector717th out of 905 stocksPharmaceutical Preparations Industry338th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 4 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.81% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Korro Bio has recently increased by 21.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRRO. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.80% of the stock of Korro Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.64) to ($10.73) per share.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Korro Bio Stock (NASDAQ:KRRO)Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More KRRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRRO Stock News HeadlinesMay 30, 2024 | globenewswire.comKorro to Participate in Upcoming June Investor and Scientific ConferencesMay 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic ProfileMay 20, 2024 | globenewswire.comKorro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International ConferenceMay 18, 2024 | finance.yahoo.comKorro Bio, Inc. (KRRO)May 15, 2024 | markets.businessinsider.comKorro Bio Earns Buy Rating from Analyst Mitchell Kapoor on Groundbreaking RNA Editing Technology and Strong Preclinical ResultsMay 15, 2024 | finanznachrichten.deKorro Bio, Inc.: Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerMay 15, 2024 | investorplace.comKRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024May 14, 2024 | globenewswire.comKorro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerApril 18, 2024 | globenewswire.comKorro Announces $70 Million Private PlacementApril 1, 2024 | globenewswire.comKorro to Participate in Upcoming Investor ConferencesMarch 26, 2024 | globenewswire.comKorro Reports Full Year 2023 Financial Results and Highlights Recent ProgressFebruary 27, 2024 | globenewswire.comKorro to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 18, 2024 | seekingalpha.comKorro Bio: An Interesting Platform With A Very Long HorizonSee More Headlines Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$122.50 High Stock Price Target$180.00 Low Stock Price Target$90.00 Potential Upside/Downside+164.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.45% Return on Assets-59.51% Debt Debt-to-Equity RatioN/A Current Ratio13.18 Quick Ratio13.18 Sales & Book Value Annual Sales$14.07 million Price / Sales30.57 Cash FlowN/A Price / Cash FlowN/A Book Value$21.19 per share Price / Book2.19Miscellaneous Outstanding Shares9,270,000Free Float7,715,000Market Cap$430.13 million OptionableNo Data Beta2.23 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Nessan Bermingham Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $202.14kMr. Ram Aiyar MBA (Age 46)Ph.D., CEO, President & Director Comp: $844.87kDr. Jean-Francois Formela M.D. (Age 67)MBA, Co-Founder & Director Comp: $8.21kMr. Vineet Agarwal M.B.A. (Age 42)Chief Financial Officer Comp: $811.77kDr. Steven L. Colletti Ph.D. (Age 58)Chief Scientific Officer Comp: $592.89kMr. Andrew Fraley Ph.D.Co-Founder & CTOMr. Josh Rosenthal Ph.D.Co-Founder & AdvisorMr. Todd Chappell (Age 51)Chief Operating Officer Ms. Shelby Walker J.D. (Age 49)Senior VP & General Counsel Mr. Ravi Ramadas Ph.D.Vice President of Business & Corporate DevelopmentMore ExecutivesKey CompetitorsGalapagosNASDAQ:GLPGKeros TherapeuticsNASDAQ:KROSEvotecNASDAQ:EVOProtagonist TherapeuticsNASDAQ:PTGXNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 621 shares on 5/17/2024Ownership: 4.522%Vanguard Group Inc.Sold 4,307 shares on 5/10/2024Ownership: 3.324%Venture Opportunity Fund AtlasBought 17,857 shares on 4/22/2024Total: $999,992.00 ($56.00/share)David L LucchinoSold 1,156 sharesTotal: $43,569.64 ($37.69/share)View All Insider TransactionsView All Institutional Transactions KRRO Stock Analysis - Frequently Asked Questions Should I buy or sell Korro Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Korro Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRRO shares. View KRRO analyst ratings or view top-rated stocks. What is Korro Bio's stock price target for 2024? 4 brokers have issued 1-year price targets for Korro Bio's stock. Their KRRO share price targets range from $90.00 to $180.00. On average, they expect the company's stock price to reach $122.50 in the next twelve months. This suggests a possible upside of 164.0% from the stock's current price. View analysts price targets for KRRO or view top-rated stocks among Wall Street analysts. How have KRRO shares performed in 2024? Korro Bio's stock was trading at $47.93 at the beginning of the year. Since then, KRRO stock has decreased by 3.2% and is now trading at $46.40. View the best growth stocks for 2024 here. Are investors shorting Korro Bio? Korro Bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 150,500 shares, an increase of 21.4% from the April 30th total of 124,000 shares. Based on an average daily trading volume, of 39,100 shares, the days-to-cover ratio is currently 3.8 days. Currently, 2.8% of the shares of the stock are short sold. View Korro Bio's Short Interest. When is Korro Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our KRRO earnings forecast. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) announced its earnings results on Tuesday, May, 14th. The company reported ($2.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.36) by $0.08. Who are Korro Bio's major shareholders? Korro Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (4.52%) and Vanguard Group Inc. (3.32%). Insiders that own company stock include David L Lucchino and Venture Opportunity Fund Atlas. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRRO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredNvidia has Apple and Microsoft within striking rangeA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. W...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
